{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T12:48:10Z","timestamp":1790513290063,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.jaad.2018.01.029","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T14:28:20Z","timestamp":1517408900000},"page":"97-103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["A prospective study comparing patients with early and late relapsing pemphigus treated with rituximab"],"prefix":"10.1016","volume":"79","author":[{"given":"Marwah Adly","family":"Saleh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2018.01.029_bib1","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00403-014-1531-1","article-title":"Geographic variations in epidemiology of two autoimmune bullous diseases: pemphigus and bullous pemphigoid","volume":"307","author":"Alpsoy","year":"2015","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaad.2018.01.029_bib2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/1346-8138.12676","article-title":"Pemphigus in the Arab world","volume":"42","author":"Saleh","year":"2015","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2018.01.029_bib3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ijwd.2015.01.002","article-title":"Autoimmune blistering diseases in females: a review","volume":"1","author":"Zhao","year":"2015","journal-title":"Int J Womens Dermatol"},{"key":"10.1016\/j.jaad.2018.01.029_bib4","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0065-2776(08)60503-9","article-title":"Cell adhesion molecules as targets of autoantibodies in pemphigus and pemphigoid, bullous diseases due to defective epidermal cell adhesion","volume":"53","author":"Stanley","year":"1993","journal-title":"Adv Immunol"},{"key":"10.1016\/j.jaad.2018.01.029_bib5","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1600-0625.2006.00499_1.x","article-title":"Are desmoglein autoantibodies essential for the immunopathogenesis of pemphigus vulgaris, or just \u201cwitnesses of disease\u201d?","volume":"15","author":"Amagai","year":"2006","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaad.2018.01.029_bib6","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1046\/j.1365-2230.2000.00624.x","article-title":"Diagnosis of pemphigus by ELISA: a critical evaluation of two ELISAs for the detection of antibodies to the major pemphigus antigens, desmoglein 1 and 3","volume":"25","author":"Harman","year":"2000","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2018.01.029_bib7","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1600-0625.2010.01069.x","article-title":"Novel ELISA systems for antibodies to desmoglein 1 and 3: correlation of disease activity with serum autoantibody levels in individual pemphigus patients","volume":"19","author":"Schmidt","year":"2010","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.jaad.2018.01.029_bib8","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1046\/j.1365-2133.1999.02752.x","article-title":"Usefulness of enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigus","volume":"140","author":"Amagai","year":"1999","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.01.029_bib9","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance","volume":"22","author":"Smith","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.jaad.2018.01.029_bib10","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1056\/NEJMoa062930","article-title":"Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin","volume":"355","author":"Ahmed","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2018.01.029_bib11","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1001\/jamadermatol.2014.2421","article-title":"First line treatment of pemphigus vulgaris with a combination of rituximab and high-potency topical corticosteroids","volume":"151","author":"Ingen-Housz-Oro","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2018.01.029_bib12","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2018.01.029_bib13","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/archderm.143.8.1033","article-title":"Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature","volume":"143","author":"Cianchini","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2018.01.029_bib14","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1038\/jid.2008.178","article-title":"B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses","volume":"128","author":"Mouquet","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2018.01.029_bib15","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1001\/archdermatol.2012.1522","article-title":"Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients","volume":"148","author":"Lunardon","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2018.01.029_bib16","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jaad.2011.12.019","article-title":"Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up","volume":"67","author":"Reguiai","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.01.029_bib17","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1038\/jid.2009.72","article-title":"Reliability and convergent validity of two outcome instruments for pemphigus","volume":"129","author":"Rosenbach","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2018.01.029_bib18","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus","volume":"58","author":"Murrell","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.01.029_bib19","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.jaad.2015.10.051","article-title":"Immunologic prediction of relapse in patients with pemphigus vulgaris (PV) in clinical remission","volume":"74","author":"Daneshpazhooh","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2018.01.029_bib20","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/1523-1747.ep12274679","article-title":"Experimentally induced pemphigus vulgaris in neonatal BALB\/c mice: a time-course study of clinical, immunologic, ultrastructural, and cytochemical changes","volume":"84","author":"Takahashi","year":"1985","journal-title":"J Invest Dermatol"},{"issue":"Suppl 1","key":"10.1016\/j.jaad.2018.01.029_bib21","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000246938","article-title":"Correlation of subclasses of IgG with disease activity in pemphigus vulgaris","volume":"189","author":"Bhol","year":"1994","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2018.01.029_bib22","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1046\/j.1365-2133.2001.04132.x","article-title":"The severity of cutaneous and oral pemphigus is related to desmoglein 1 and 3 antibody levels","volume":"144","author":"Harman","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.01.029_bib23","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1080\/08916930600972040","article-title":"Immunoadsorption in pemphigus","volume":"39","author":"Eming","year":"2006","journal-title":"Autoimmunity"},{"key":"10.1016\/j.jaad.2018.01.029_bib24","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/dth.12145","article-title":"Specific immunoadsorption of pathogenic autoantibodies in pemphigus requires the entire ectodomains of desmogleins","volume":"27","author":"Yancey","year":"2014","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2018.01.029_bib25","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2133.2011.10658.x","article-title":"Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy","volume":"166","author":"Feldman","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2018.01.029_bib26","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00403-017-1754-z","article-title":"Rituximab treatment in pemphigus vulgaris: effect on circulating Tregs","volume":"309","author":"El-Zawahry","year":"2017","journal-title":"Arch Dermatol Res"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218301488?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218301488?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:45:55Z","timestamp":1759272355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962218301488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0190962218301488"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2018.01.029","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A prospective study comparing patients with early and late relapsing pemphigus treated with rituximab","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2018.01.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}